SCHEMBL263979

SCHEMBL263979

Clc1ccccc1C1CNCCN1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.42
HTR2A P28223 2/20 0.38
HTR2B P41595 2/20 0.38
DRD1 P21728 1/20 0.37
DRD5 P21918 1/20 0.37
SLC6A3 Q01959 2/20 0.37
GAA P10253 1/20 0.37
AGTR1 P30556 1/20 0.37
TP53 P04637 1/20 0.37
RECQL P46063 1/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
PARP1 P09874 1/20 0.36
DPP4 P27487 1/20 0.36
SLC6A2 P23975 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7249716 0.98 HTR2C (0.41) HTR2CHTR2AHTR2BDRD1DRD5
Hydrochloric Acid SCHEMBL10382642 0.98 HTR2C (0.41) HTR2CHTR2AHTR2BDRD1DRD5
SCHEMBL4778750 0.86 HTR2C (0.44) HTR2CHTR2AHTR2BSLC6A3GAA
Hydrochloric Acid SCHEMBL27355288 0.84 HTR2C (0.43) HTR2CHTR2AHTR2BSLC6A3GAA
SCHEMBL28782592 0.84 SLC6A3 (0.47) HTR2CHTR2AHTR2BSLC6A3GAA
SCHEMBL1638955 0.79 HTR2C (0.44) HTR2CHTR2AHTR2BGAAAGTR1
SCHEMBL16165 0.79 HTR2C (0.45) HTR2CHTR2AHTR2BSLC6A2
SCHEMBL4522448 0.78 GID4 (0.39) HTR2CHTR2AHTR2BDRD1DRD5
SCHEMBL7332257 0.78 HTR2C (0.50) HTR2CHTR2AHTR2BTAAR1
SCHEMBL4533549 0.78 KDM1A (0.40) HTR2CHTR2AHTR2BSLC6A3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
CN-122036605-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2026-05-15 CN disclosed
CN-119948015-A Novel sulfonamides and their use as neuroprotective and/or nerve repair agents 基因密码公司 2025-05-06 CN disclosed
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K VIVIDION THERAPEUTICS, INC. 2025-01-23 US disclosed
US-20230174484-A1 ANTAGONISTS OF GPR39 PROTEIN UNIV OREGON HEALTH & SCIENCE (US) 2023-06-08 US disclosed
CN-115996908-A Antagonists of GPR39 proteins 俄勒冈健康科学大学 2023-04-21 CN disclosed
EP-4143163-A1 ANTAGONISTS OF GPR39 PROTEIN Oregon Health & Science University (US) 2023-03-08 EP disclosed
WO-2021222858-A1 ANTAGONISTS OF GPR39 PROTEIN OREGON HEALTH & SCIENCE UNIVERSITY (US) 2021-11-04 WO disclosed
CN-110337245-A The sprout inhibitor and triazole carbamide compound of witchweed lactone acceptor inhibitor, agricultural composition and application thereof, only angle gold seeds 国立大学法人东京大学 2019-10-15 CN disclosed
EP-0630373-A1 INDOLE DERIVATIVES AS 5HT1C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-12-28 EP disclosed
WO-1994022871-A1 THIENO-INDOLE DERIVATIVES AS 5HT2c AND 5HT2b ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-10-13 WO disclosed
WO-1994014801-A1 HETEROCYCLIC UREA DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-07-07 WO disclosed
WO-1994004533-A1 CONDENSED INDOLE DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1994-03-03 WO disclosed
WO-1993018028-A1 INDOLE DERIVATIVES AS 5HT1C ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1993-09-16 WO disclosed
EP-0211746-B1 PHENYL-PIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTICAL USE LABORATOIRE L. LAFON Société anonyme dite: (FR) 1990-05-23 EP disclosed
EP-0211746-A1 Phenyl-piperazine derivatives, process for their preparation and therapeutical use LABORATOIRE L. LAFON Société anonyme dite: (FR) 1987-02-25 EP disclosed
US-4166180-A 2-ARYLPIPERAZINE DERIVATIVES AND THE PREPARATION THEREOF HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1979-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026721-A1 COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K KRAS, HRAS, NRAS HTR2C 3889/4885HTR2A 3820/4885HTR2B 3704/4885
US-20230174484-A1 ANTAGONISTS OF GPR39 PROTEIN GPR39, GPR139, GPR119 HTR2C 785/4885HTR2A 430/4885HTR2B 584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.